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Acute myeloid leukemia and fatal Scedosporium prolificans
sepsis after eculizumab treatment for paroxysmal nocturnal
hemoglobinuria: a case report
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Abstract: Eculizumab has become the standard of care for patients with paroxysmal nocturnal
hemoglobinuria (PNH). As more patients are treated, the long-term outcomes of these patients will become
apparent. We recently treated a patient who developed PNH in the setting of aplastic anemia. The patient
developed acute myeloid leukemia less than three years after initiating eculizumab. The patient also died
suddenly from Scedosporium sepsis during induction therapy. This patient’s course seemed more aggressive
than would be expected. The possible effect of complement blockade is discussed.
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Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal
hematopoietic stem cell disorder caused by a somatic mutation
in phosphatidylinositol N-acetylglucosaminyltransferase
subunit A (PIGA), whose gene product is required for the
synthesis of glycosyl-phosphatidyl inositol (GPI) anchors (1).
Loss of GPI anchors results in a deficiency of the protective
complement inhibitors CD55 and CD59 on erythrocytes,
thus making them susceptible to complement-mediated
lysis. The clinical hallmarks of PNH include acquired
hemolytic anemia, bone marrow failure and life-threatening
thrombosis (2). Eculizumab, a monoclonal antibody that
binds to the complement protein C5, protects PNH red
cells from complement mediated intravascular hemolysis
by inhibiting the formation of the membrane attack
complex (C5–C9) (3,4). In two double-blind, randomized,
placebo-controlled trials, eculizumab reduced intravascular
hemolysis and improved quality of life in patients with
PNH who received the drug (5,6). Although eculizumab has
immunosuppressive properties, there is only one published
case report of a malignancy (melanoma) developing on
eculizumab (7). Although it is difficult to assess causality
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from individual case reports, it is helpful to see the spectrum
of malignancies that occur in these patients.
Case presentation
Currently we describe a patient who developed acute myeloid
leukemia while on treatment with eculizumab. This case
received a waiver of consent from the Institutional Review
Board of New York Medical College, Valhalla, NY, USA.
A 71-year-old male with no significant past medical history
presented to his primary care doctor in December 2013 with
complaints of fatigue and dyspnea on exertion. A complete
blood count (CBC) showed a white blood count (WBC) of
5.8 × 109/L, hemoglobin of 13.1 gm/dL and a platelet count
of 60 × 109/L. The patient was initially observed, however
follow-up laboratories in February 2014 showed marked
deterioration. The white blood count was 3.3 × 109/L with
40% neutrophils, 56% lymphocytes and 4% monocytes,
the hemoglobin was 7.7 gm/dL and the platelet count was
8 × 109/L. The patient was referred to our center at that
time. A bone marrow biopsy was hypoplastic (cellularity
10%) with normal myeloid and megakaryocytic morphology.
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There was a rare dysplastic erythroid cell (<10%) and a blast
count of less than 1%. Flow cytometry and cytogenetics
were normal, as was a myelodysplastic syndrome (MDS)
FISH panel. An MDS next-generation sequencing panel that
included ASXL1, RUNX1, EZH2, ETV6, and TP53 showed
no mutations. Other laboratories, including reticulocyte
count, Coombs, LDH, haptoglobin, folate, iron studies,
hepatitis panel, and human immunodeficiency virus (HIV),
parvovirus and Lyme serologies were unremarkable. His
initial B12 level was low, however, he had no response to
B12 injections. PNH testing showed that 0.1% of red cells
lacked CD59 expression, and 5% of monocytes and 2% of
granulocytes showed downregulation of CD59 and lack of
FLAER expression.
In March 2014, the patient was treated for aplastic
anemia with anti-thymocyte globulin, 40 mg/kg daily
for 4 days, steroids and cyclosporin. Only 2 months later
the patient developed clinical evidence of intravascular
hemolysis with rapid expansion of his PNH clone (red
cells 0.25%, granulocytes 22%, monocytes 27%). After
vaccination, he began therapy with eculizumab in July
of 2014. He received ongoing therapy with eculizumab
combined with cyclosporine and became transfusion in
dependent with a normal WBC, hemoglobin of 11 gm/dL
and peak platelet count of 71 × 109/L.
In May of 2017, the patient was referred back to us
for evaluation of worsening pancytopenia. His WBC was
4.1 × 10 9/L with 23% neutrophils, 53% lymphocytes,
16% monocytes, 1% eosinophils, 1% basophils, and 6%
blasts. The hemoglobin was 9.4 gm/dL, and the platelet
count was 19 × 10 9/L. A bone marrow biopsy showed
acute myeloid leukemia with 55% blasts that expressed
CD34, CD117, partial CD33, dim CD13, and HLA-DR.
Cytogenetics demonstrated 46,XY,del[7](q22q34)[2]/46,
XY[18]. Next-generation sequencing revealed mutations in
PALB2 (c.311C>T; p.P104L, 50%), PHF6 (c.834+2T>G,
52%), and RUNX1 (c.967_967+1insA, 10%, and
c.593A>G; p.D198G, 22%).
The patient was treated with CLAG-Ida (cladribine,
cytarabine, granulocyte colony stimulating factor and
idarubicin). On day 7 the patient developed neutropenic
fever and received cefepime and vancomycin. A urine
culture grew E. coli. On day 14 the patient suddenly
developed septic shock and required intubation and pressor.
Blood cultures grew vancomycin-resistant enterococcus
and mold that was subsequently identified as Scedosporium
prolificans. Despite maximal support the patient expired on
day 17 of therapy.
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Discussion
Eculizumab has changed the outcome of patients with
PNH (8). In a report of the long-term results of eculizumab
in 195 PNH patients who were treated over a 66-month
period, only four deaths occurred, resulting in an estimated
3-year survival rate of 97.6% (9). All patients demonstrated
a reduction in LDH, and 96.4% of patients remained free
of thromboembolic events.
Eculizumab is a powerful inhibitor of the complement
pathway. It is thus expected that immunological pathways
that rely on complement activation could be adversely
affected. For example, it is well documented that patients
treated with eculizumab are at increased risk of infections,
particularly Neisseria meningitidis infections (10). In the
long-term study, 40 patients reported a total of 67 serious
infections, including two cases of meningococcal sepsis (9).
These infections can occur even after appropriate
vaccination and are similar to those seen in patients with
hereditary disorders of complement (11).
Classically, T-cell immunity is thought to be the primary
host defense mechanism preventing the development
and propagation of malignant diseases. More recently, a
relationship between imbalanced complement activation in
the tumor microenvironment and suppression of antitumor
immune responses has been discovered (12). Despite these
findings, there are only limited reports of malignancies
occurring in patients treated with eculizumab. In the longterm study, one patient developed MDS and was taken
off study to pursue a stem cell transplant (9). Manganoni
et al. reported a patient who developed two melanomas
simultaneously after having received eculizumab for 6 years
as treatment of PNH (7). There was no family history of
skin cancers and no prior dysplastic nevi in this patient.
Further post marketing studies are needed to determine
the incidence of malignancies in patients treated with
eculizumab.
Progression to acute myeloid leukemia is a known
complication of aplastic anemia in patients treated with
immunosuppressive therapy. On average, the incidence
of MDS and acute myelocytic leukemia (AML) after
immunosuppressive therapy ranges from 5–15% after a
follow-up of 5–11 years (13,14). In our case, the presence
of a PNH clone at diagnosis was evidence of clonal disease
from the start, even though the patient did not meet
diagnostic criteria for MDS at that time. It is unknown if
eculizumab could have influenced the rapidity with which
our patient progressed to AML.
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Our patient expired from Scedosporium sepsis very early
into his treatment course. Although there are many reports
of Scedosporium infection occurring in leukemia patients
undergoing induction therapy or allogeneic stem cell
transplantation, these life threatening fungal infections
are more common in patients with multiply-relapsed
disease, and in those who have either been neutropenic
for prolonged periods of time, or in those receiving T-cell
suppressing therapies after transplant (15). It is unknown
whether pretreatment with eculizumab increased our
patient’s risk of developing a relatively rare disseminated
fungal infection so early in his treatment course.

Page 3 of 3

5.

6.

7.

8.

Acknowledgements
None.
9.

Footnote
Conflicts of Interest: K Seiter is on the speaker’s bureau
of Alexion Pharmaceuticals. The other authors have no
conflicts of interest to declare.

10.

Informed Consent: Written informed consent was obtained
from the patient for publication of this manuscript and any
accompanying images.

11.

References
1.

2.

3.

4.

Hill A, DeZern AE, Kinoshita T, et al. Paroxysmal
nocturnal haemoglobinuria. Nat Rev Dis Primers
2017;3:17028.
Hillmen P, Lewis SM, Bessler M, et al. Natural history
of paroxysmal nocturnal hemoglobinuria. N Engl J Med
1995;333:1253-8.
Thomas TC, Rollins SA, Rother RP, et al. Inhibition of
complement activity by humanized anti-C5 antibody and
single-chain Fv. Mol Immunol 1996;33:1389-401.
Brachet G, Bourquard T, Gallay N, et al. Eculizumab
epitope on complement C5: Progress towards a better

12.
13.

14.

15.

understanding of the mechanism of action. Mol Immunol
2016;77:126-31.
Hillmen P, Young NS, Schubert J, et al. The complement
inhibitor eculizumab in paroxysmal nocturnal
hemoglobinuria. N Engl J Med 2006;355:1233-43.
Brodsky RA, Young NS, Antonioli E, et al. Multicenter
phase 3 study of the complement inhibitor eculizumab
for the treatment of patients with paroxysmal nocturnal
hemoglobinuria. Blood 2008;111:1840-7.
Manganoni AM, Pavoni L, Facchetti F, et al. Melanoma
in a patient in treatment with eculizumab. Ann Hematol
2012;91:135-6.
Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment
with eculizumab in paroxysmal nocturnal hemoglobinuria:
sustained efficacy and improved survival. Blood
2011;117:6786-92.
Hillmen P, Muus P, Röth A, et al. Long-term safety and
efficacy of sustained eculizumab treatment in patients with
paroxysmal nocturnal haemoglobinuria. Br J Haematol
2013;162:62-73.
McNamara LA, Topaz N, Wang X, et al. High risk for
invasive meningococcal disease among patients receiving
eculizumab (soliris) despite receipt of meningococcal
vaccine. MMWR Morb Mortal Wkly Rep 2017;66:734-7.
Frazer-Abel A, Sepiashvili L, Mbughuni MM, et al.
Overview of laboratory testing and clinical presentations
of complement deficiencies and dysregulation. Adv Clin
Chem 2016;77:1-75.
Afshar-Kharghan V. The role of the complement system in
cancer. J Clin Invest 2017;127:780-9.
Najean Y, Haguenauer O. Long-term (5 to 20 years)
Evolution of nongrafted aplastic anemias. The Cooperative
Group for the Study of Aplastic and Refractory Anemias.
Blood 1990;76:2222-8.
Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic
Mutations and Clonal Hematopoiesis in Aplastic Anemia.
N Engl J Med 2015;373:35-47.
Caira M, Girmenia C, Valentini CG, et al. Scedosporiosis
in patients with acute leukemia: a retrospective multicenter
report. Haematologica 2008;93:104-10.

doi: 10.21037/sci.2017.12.04
Cite this article as: Hanmantgad M, Nog R, Seiter K.
Acute myeloid leukemia and fatal Scedosporium prolificans
sepsis after eculizumab treatment for paroxysmal nocturnal
hemoglobinuria: a case report. Stem Cell Investig 2017;4:100.

© Stem Cell Investigation. All rights reserved.

sci.amegroups.com

Stem Cell Investig 2017;4:100

